



*FFW*

Application of:

Dennis L. Panicali et al.

Application No.: 10/660,369

Group No.: 1614

Filed: 09/11/2003

Examiner: To be assigned

Confirmation No.: 5464

Customer No.: 50187

For:

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL  
COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE  
IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR  
EFFECTS IN VIVO

**CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the MAIL STOP PETITION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

December 7, 2005

Date

Linda M. Ginsberg

(type or print name of person mailing paper)

(signature of person mailing paper)

**MAIL STOP PETITION**

**Director of the US Patent and Trademark Office**

**PO Box 1450**

**Alexandria, VA 22313-1450**

**AMENDMENT, REQUEST AND FEE TO DELETE AND/OR  
ADD TO ORIGINAL ERRONEOUSLY NAMED OR NOT NAMED  
INVENTOR(S) IN—NONPROVISIONAL APPLICATION—DECLARATION  
(37 C.F.R. § 1.48(a))**

1. This amendment and request is to correct the incorrect original naming of inventor(s) in the declaration under 37 C.F.R. § 1.48(a) as set forth and filed on January 22, 2004.
2. Addition of Inventor:  
  
Jeffrey Schlom
3. Attachments:  
  
(a) Statement of Non-Deceptive Intent, Jeffrey Schlom, as required by 37 C.F.R. § 1.48(a);

12/13/2005 EFLORES 00000020 500850 10660369

01 FC:1464

130.00 DA

In re application of:

Dennis L. Panicali et al.

Application No.:

10/660,369

Group No.:

1614

Filed:

09/11/2003

Examiner:

To be assigned

Confirmation No.:

5464

Customer No.:

50187

For:

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL  
COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE IMMUNOSTIMULATORY  
PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN VIVO

(b) Assent of the Assignee to Correct Inventorship and Statement Under 37 C.F.R.  
§ 3.73(b):

- (i) Therion Biologics Corporation; and
- (ii) The Trustees of the Leland Stanford Junior University


4. Fee Payment (37 C.F.R. § 1.17(i))

The fee required by 37 C.F.R. § 1.17(h) is paid as follows:


The Commissioner is authorized to charge the NIXON PEABODY LLP Deposit Account  
No. 50-0850 in the amount of \$130.00. Any fee deficiencies or overpayments may be  
charged/credited to said account. A duplicate copy of this paper is submitted herewith.

Date: December 7, 2005

Respectfully submitted,



Ronald I. Eisenstein (Reg. No. 30,628)  
NIXON PEABODY LLP  
100 Summer Street  
Boston, MA 02110  
(617) 345-6054



Re application of: Dennis L. Panicali et al.

Application No.: 10/660,369      Group No.: 1614  
Filed: 09/11/2003      Examiner: To be assigned  
Confirmation No.: 5464      Customer No.: 50187  
For: TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO  
EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1  
AND LFA-3 AND INDUCE IMMUNOSTIMULATORY  
PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN  
VIVO

**CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the MAIL STOP PETITION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

12/7/05  
Date

Linda M. Ginsberg

(type or print name of person mailing paper)

[Signature]  
(signature of person mailing paper)

**MAIL STOP PETITION**


**Director of the US Patent and Trademark Office**  
**PO Box 1450**  
**Alexandria, VA 22313-1450**

**STATEMENT OF NON-DECEPTIVE INTENT TO ACCOMPANY  
REQUEST FOR CORRECTION OF INVENTORSHIP  
UNDER 37 C.F.R. §1.48(A)**

I, the person who is being added as an inventor by the Request for Correction of Inventorship being submitted concurrently herewith to correct the inventorship of this patent application do hereby declare that the inventorship error in failing to include my name as an inventor on this patent occurred without any deceptive intention on my part.

11-18-05  
Date

[Signature]  
Jeffrey Schlom, Inventor



PEABODY LLP  
101 Federal Street  
Boston, Massachusetts 02110

Attorney's Docket No. 700953-54440

Page 1 of 4

### SUPPLEMENTAL DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed at 201) below or an original, first and joint inventor (if plural names are listed at 201-208 below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

#### TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1, AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN-VIVO

which is described and claimed in:

- ☐ the specification attached hereto.
- ☒ the specification in U.S. Application Serial Number 10/660,369 filed on September 11, 2003;
- ☐ the specification in PCT International Application Number [REDACTED] filed on [REDACTED], as amended on [REDACTED].

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a). I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign/PCT Applications and Any Priority Claims Under 35 U.S.C. §119:			
Application No.	<u>Filing Date</u>	<u>Country</u>	<u>Priority Claimed under 35 U.S.C. §119?</u>
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to

disclose material information as defined in 37 CFR §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Prior U.S. Applications or PCT International Applications Designating the U.S-Benefit under 35 U.S.C. §120					
U.S. Applications		Status (Check One)			
Application Serial No.	U.S. Filing Date	Patented	Pending	Abandoned	
PCT Applications Designating the U.S.					
Application No.	Filing Date	U.S. Serial No. Assigned			

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)  
(35 U.S.C. §119(e))**

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

<u>Applicant</u>	<u>Provisional Application Number</u>	<u>Filing Date</u>
Dennis L. Panicali, et al.	60/410,161	September 12, 2002

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) with full powers of association, substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Ronald I. Eisenstein (Reg. No. 30,628)	David S. Resnick (Reg. No. 34,235)	Michael L. Goldman (Reg. No. 30,727)
Nicole L.M. Valtz (Reg. No. 47,150)	Leena Karttunen (37 CFR Sec. 10.9(b))	Georgia Evans (Reg. No. 44,957)
Lisa A. Dolak (Reg. No. 35,491)	Joseph Noto (Reg. No. 32,163))	Gunnar G. Leinberg (Reg. No. 35,584)
Edwin V. Merkel (Reg. No. 40,087)		


<b>SEND CORRESPONDENCE TO:</b> David S. Resnick NIXON PEABODY LLP 100 Summer Street Boston, Massachusetts 02110	<b>DIRECT TELEPHONE CALLS TO:</b>  David S. Resnick (617) 345-6057
---	---


201	FULL NAME OF INVENTOR	LAST NAME <b>PANICALI</b>	FIRST NAME <b>DENNIS</b>	MIDDLE NAME <b>L.</b>
	RESIDENCE & CITIZENSHIP	CITY <b>Acton</b>	STATE OR FOREIGN COUNTRY <b>MA</b>	COUNTRY OF CITIZENSHIP <b>U.S.</b>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>114 Nonset Path</b>	CITY <b>Acton</b>	STATE OR COUNTRY AND ZIP CODE <b>MA 01720</b>

202	FULL NAME OF INVENTOR	LAST NAME <b>LEVY</b>	FIRST NAME <b>RONALD</b>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <b>Stanford</b>	STATE OR FOREIGN COUNTRY <b>CA</b>	COUNTRY OF CITIZENSHIP <b>U.S.</b>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>966 Mears Court</b>	CITY <b>Stanford</b>	STATE OR COUNTRY AND ZIP CODE <b>CA 94305</b>

203	FULL NAME OF INVENTOR	LAST NAME <b>SCHLOM</b>	FIRST NAME <b>JEFFREY</b>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP <b>U.S.</b>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>10301 Sorrel Ave.</b>	CITY <b>Potomac</b>	STATE OR COUNTRY AND ZIP CODE <b>MD 20854</b>

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature of Inventor <b>201 – Dennis L. Panicali</b>	Date:
	8-22-05
Signature of Inventor <b>202 – Ronald Levy</b>	Date:
Signature of Inventor <b>203 – Jeffrey Schlom</b>	Date:



**NIXON PEABODY LLP**  
100 Summer Street  
Boston, Massachusetts 02110

**Attorney's Docket No. 700953-54440**

**Page 1 of 4**

**SUPPLEMENTAL DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed at 201) below or an original, first and joint inventor (if plural names are listed at 201-208 below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**TRANSDUCE NEOPlastic CELL PREPARATIONS ABLE TO EXPRESS T-CELL  
COSTIMULATORY MOLECULES B7.1, ICAM-1, AND LFA-3 AND INDUCE  
IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR  
EFFECTS IN-VIVO**

which is described and claimed in:

- ☐ the specification attached hereto.
- ☒ the specification in U.S. Application Serial Number 10/660,369 filed on September 11, 2003;
- ☐ the specification in PCT International Application Number [REDACTED] filed on [REDACTED], as amended on [REDACTED].

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a). I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign/PCT Applications and Any Priority Claims Under 35 U.S.C. §119:			
Application No.	Filing Date	Country	Priority Claimed under 35 U.S.C. §119?
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO



I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Prior U.S. Applications or PCT International Applications Designating the U.S-Benefit under 35 U.S.C. §120					
U.S. Applications			Status (Check One)		
Application Serial No.	U.S. Filing Date		Patented	Pending	Abandoned
PCT Applications Designating the U.S.					
Application No.	Filing Date	U.S. Serial No. Assigned			

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)  
(35 U.S.C. §119(e))**

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

<u>Applicant</u>	<u>Provisional Application Number</u>	<u>Filing Date</u>
Dennis L. Panicali, et al.	60/410,161	September 12, 2002

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) with full powers of association, substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Ronald I. Eisenstein (Reg. No. 30,628)	David S. Resnick (Reg. No. 34,235)	Michael L. Goldman (Reg. No. 30,727)
Nicole L.M. Valtz (Reg. No. 47,150)	Leena Karttunen (37 CFR Sec. 10.9(b))	Georgia Evans (Reg. No. 44,957)
Lisa A. Dolak (Reg. No. 35,491)	Joseph Noto (Reg. No. 32,163))	Gunnar G. Leinberg (Reg. No. 35,584)
Edwin V. Merkel (Reg. No. 40,087)		


<b>SEND CORRESPONDENCE TO:</b> David S. Resnick NIXON PEABODY LLP 100 Summer Street Boston, Massachusetts 02110	<b>DIRECT TELEPHONE CALLS TO:</b>  David S. Resnick (617) 345-6057
---	---

201	FULL NAME OF INVENTOR	LAST NAME <b>PANICALI</b>	FIRST NAME <b>DENNIS</b>	MIDDLE NAME <b>L.</b>
	RESIDENCE & CITIZENSHIP	CITY <b>Acton</b>	STATE OR FOREIGN COUNTRY <b>MA</b>	COUNTRY OF CITIZENSHIP <b>U.S.</b>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>114 Nonset Path</b>	CITY <b>Acton</b>	STATE OR COUNTRY AND ZIP CODE <b>MA 01720</b>

202	FULL NAME OF INVENTOR	LAST NAME <b>LEVY</b>	FIRST NAME <b>RONALD</b>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <b>Stanford</b>	STATE OR FOREIGN COUNTRY <b>CA</b>	COUNTRY OF CITIZENSHIP <b>U.S.</b>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>966 Mears Court</b>	CITY <b>Stanford</b>	STATE OR COUNTRY AND ZIP CODE <b>CA 94305</b>

203	FULL NAME OF INVENTOR	LAST NAME <b>SCHLOM</b>	FIRST NAME <b>JEFFREY</b>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP <b>U.S.</b>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>10301 Sorrel Ave.</b>	CITY <b>Potomac</b>	STATE OR COUNTRY AND ZIP CODE <b>MD 20854</b>

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature of Inventor 201 – Dennis L. Panicali	Date:
Signature of Inventor 202 – Ronald Levy	Date:
	10/4/05
Signature of Inventor 203 – Jeffrey Schlom	Date:



**WILSON PEABODY LLP**  
101 Federal Street  
Boston, Massachusetts 02110

**Attorney's Docket No. 700953-54440**

**Page 1 of 4**

### **SUPPLEMENTAL DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed at 201) below or an original, first and joint inventor (if plural names are listed at 201-208 below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

#### **TRANSDUCE NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1, AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN-VIVO**

which is described and claimed in:

- ☐ the specification attached hereto.
- ☒ the specification in U.S. Application Serial Number 10/660,369 filed on September 11, 2003;
- ☐ the specification in PCT International Application Number  filed on , as amended on .

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a). I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

<b>Prior Foreign/PCT Applications and Any Priority Claims Under 35 U.S.C. §119:</b>			
<b>Application No.</b>	<b><u>Filing Date</u></b>	<b><u>Country</u></b>	<b><u>Priority Claimed under 35 U.S.C. §119?</u></b>
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to

disclose material information as defined in 37 CFR §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Prior U.S. Applications or PCT International Applications Designating the U.S-Benefit under 35 U.S.C. §120					
U.S. Applications			Status (Check One)		
Application Serial No.	U.S. Filing Date	Patented	Pending	Abandoned	
PCT Applications Designating the U.S.					
Application No.	Filing Date	U.S. Serial No. Assigned			

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)  
(35 U.S.C. §119(e))**

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

<u>Applicant</u>	<u>Provisional Application Number</u>	<u>Filing Date</u>
Dennis L. Panicali, et al.	60/410,161	September 12, 2002

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) with full powers of association, substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Ronald I. Eisenstein (Reg. No. 30,628)	David S. Resnick (Reg. No. 34,235)	Michael L. Goldman (Reg. No. 30,727)
Nicole L.M. Valtz (Reg. No. 47,150)	Leena Karttunen (37 CFR Sec. 10.9(b))	Georgia Evans (Reg. No. 44,957)
Lisa A. Dolak (Reg. No. 35,491)	Joseph Noto (Reg. No. 32,163))	Gunnar G. Leinberg (Reg. No. 35,584)
Edwin V. Merkel (Reg. No. 40,087)		


<b>SEND CORRESPONDENCE TO:</b> David S. Resnick NIXON PEABODY LLP 100 Summer Street Boston, Massachusetts 02110	<b>DIRECT TELEPHONE CALLS TO:</b> David S. Resnick (617) 345-6057
---	---


201	FULL NAME OF INVENTOR	LAST NAME <b>PANICALI</b>	FIRST NAME <b>DENNIS</b>	MIDDLE NAME <b>L.</b>
	RESIDENCE & CITIZENSHIP	CITY <b>Acton</b>	STATE OR FOREIGN COUNTRY <b>MA</b>	COUNTRY OF CITIZENSHIP <b>U.S.</b>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>114 Nonset Path</b>	CITY <b>Acton</b>	STATE OR COUNTRY AND ZIP CODE <b>MA 01720</b>

202	FULL NAME OF INVENTOR	LAST NAME <b>LEVY</b>	FIRST NAME <b>RONALD</b>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <b>Stanford</b>	STATE OR FOREIGN COUNTRY <b>CA</b>	COUNTRY OF CITIZENSHIP <b>U.S.</b>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>966 Mears Court</b>	CITY <b>Stanford</b>	STATE OR COUNTRY AND ZIP CODE <b>CA 94305</b>

203	FULL NAME OF INVENTOR	LAST NAME <b>SCHLOM</b>	FIRST NAME <b>JEFFREY</b>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP <b>U.S.</b>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>10301 Sorrel Ave.</b>	CITY <b>Potomac</b>	STATE OR COUNTRY AND ZIP CODE <b>MD 20854</b>

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature of Inventor 201 – Dennis L. Panicali	Date:
Signature of Inventor 202 – Ronald Levy	Date:
Signature of Inventor 203 – Jeffrey Schlom	Date:
	11-18-05



Application of:

Dennis L. Panicali et al.

Application No.: 10/660,369

Group No.: 1614

Filed: 09/11/2003

Examiner: To be assigned

Confirmation No.: 5464

Customer No.: 50187

For: TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL  
COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE  
IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR  
EFFECTS IN VIVO

**CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the MAIL STOP PETITION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

December 7, 2005

Linda M. Ginsberg

Date

(type or print name of person mailing paper)

(signature of person mailing paper)

**MAIL STOP PETITION**

**Director of the US Patent and Trademark Office**

**PO Box 1450**

**Alexandria, VA 22313-1450**

**ASSENT OF ASSIGNEE TO CORRECTION  
AND/OR ADDITION OF INVENTOR(S)**

Name of Assignee: Therion Biologics Corporation

Address of Assignee: 76 Rogers Street  
Cambridge, MA 02142

An assignment from Dennis L. Panicali for Application Serial No. 10/660,369 was recorded in the U.S. Patent and Trademark Office on January 26, 2004 at Reel 014923, Frame 0738.



Application No.:	10/660,369	Group No.:	1614
Filed:	09/11/2003	Examiner:	To be assigned
Confirmation No.:	5464	Customer No.:	50187
For:	TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN VIVO		

Assignee hereby assents to the correction of inventorship filed herewith.

#### RIGHT OF ASSIGNEE TO TAKE ACTION

A "STATEMENT UNDER 37 C.F.R. § 373(b)" is attached.

8/22/05  
Date

John T. Li  
John T. Li  
Patent Counsel  
Therion Biologics Corporation



Serial No. 700953-54440

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Dennis L. Panicali et al.

Application No.: 10/660,369      Group No.: 1614  
Filed: 09/11/2003      Examiner: To be assigned  
Confirmation No.: 5464      Customer No.: 50187  
For: TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO  
EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1  
AND LFA-3 AND INDUCE IMMUNOSTIMULATORY  
PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN  
VIVO

**CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

December 7, 2005  
Date

Linda M. Ginsberg

(type or print name of person mailing paper)

(signature of person mailing paper)

**MAIL STOP PETITION**

**Director of the US Patent and Trademark Office**  
**PO Box 1450**  
**Alexandria, VA 22313-1450**

**STATEMENT UNDER 37 C.F.R. § 3.73(b)**  
**ESTABLISHING RIGHT OF ASSIGNEE TO TAKE ACTION**

The assignee(s) of the entire right, title and interest hereby seek(s) to take action in the PTO in this matter.

**IDENTIFICATION OF ASSIGNEE**

Name of assignee: Therion Biologics Corporation  
Type of assignee: Corporation

In re application of: Dennis L. Panicali et al.

Application No.: 10/660,369

Filed: 09/11/2003

Confirmation No.: 5464

For:

Group No.: 1614

Examiner: To be assigned

Customer No.: 50187

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL  
COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE  
IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS  
IN VIVO

### PERSON AUTHORIZED TO SIGN

Name of person authorized to sign on behalf of assignee: John T. Li

Title of person authorized to sign: Patent Counsel

### BASIS OF ASSIGNEE'S INTEREST

Ownership by the assignee is established as follows:

An assignment from the inventor(s) of the matter identified above, which was recorded in  
the PTO on January 26, 2004 at Reel 014923, Frame 0738.

### COPIES OF DOCUMENTS IN CHAIN OF TITLE

Copies of the assignment(s) or other document(s) in the chain of title are attached as follows:

Date: 8/22/05


John T. Li  
John T. Li

Title: Patent Counsel  
Therion Biologics Corporation



In re-application of: Dennis L. Panicali et al.

Application No.:	10/660,369	Group No.:	1614
Filed:	09/11/2003	Examiner:	To be assigned
Confirmation No.:	5464	Customer No.:	50187
For:	TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN VIVO		

<b>CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))</b>	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the MAIL STOP PETITION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
<u>December 7, 2005</u> Date	<u>Linda M. Ginsberg</u> (type or print name of person mailing paper)  (signature of person mailing paper)

**MAIL STOP PETITION**  
**Director of the US Patent and Trademark Office**  
**PO Box 1450**  
**Alexandria, VA 22313-1450**

**ASSENT OF ASSIGNEE TO CORRECTION  
AND/OR ADDITION OF INVENTOR(S)**

Name of Assignee: The Board of Trustees of the Leland Stanford Junior University

Address of Assignee: 1705 El Camino Real  
Palo Alto, CA 94306

An assignment from Ronald Levy for Application Serial No. 10/660,369 was recorded in the U.S. Patent and Trademark Office was recorded in the U.S. Patent and Trademark Office on January 26, 2004 at Reel 014923, Frame 0734.

. D E

Application No.:	10/660,369	Group No.:	1614
Filed:	09/11/2003	Examiner:	To be assigned
Confirmation No.:	5464	Customer No.:	50187
For:	TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN VIVO		

Assignee hereby assents to the correction of inventorship filed herewith.

### RIGHT OF ASSIGNEE TO TAKE ACTION

A "STATEMENT UNDER 37 C.F.R. § 373(b)" is attached.

Dec 5, 2005  
Date

Katharine Ku  
Name: Katharine Ku  
Title: ~~Director, Technology Licensing~~  
On behalf of The Board of Trustees of the Leland  
Stanford Junior University



Docket No. 700953-54440

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Dennis L. Panicali et al.

Application No.: 10/660,369      Group No.: 1614  
Filed: 09/11/2003      Examiner: To be assigned  
Confirmation No.: 5464      Customer No.: 50187  
For: TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO  
EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1  
AND LFA-3 AND INDUCE IMMUNOSTIMULATORY  
PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN  
VIVO

**CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

December 7, 2005

Date

Linda M. Ginsberg

(type or print name of person mailing paper)

(signature of person mailing paper)

**MAIL STOP PETITION**

**Director of the US Patent and Trademark Office**

**PO Box 1450**

**Alexandria, VA 22313-1450**

**STATEMENT UNDER 37 C.F.R. § 3.73(b)  
ESTABLISHING RIGHT OF ASSIGNEE TO TAKE ACTION**

The assignee(s) of the entire right, title and interest hereby seek(s) to take action in the PTO in this matter.

**IDENTIFICATION OF ASSIGNEE**

Name of assignee: The Board of Trustees of the Leland Stanford Junior University  
Type of assignee: Corporation

In re application of: Dennis L. Panicali et al.

Application No.: 10/660,369

Group No.: 1614

Filed: 09/11/2003

Examiner: To be assigned

Confirmation No.: 5464

Customer No.: 50187

For: TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL  
COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE  
IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS  
IN VIVO

### PERSON AUTHORIZED TO SIGN

Name of person authorized to sign on behalf of assignee: \_\_\_\_\_

Title of person authorized to sign: \_\_\_\_\_

  
Katharine Ku  
Director, Technology Licensing

### BASIS OF ASSIGNEE'S INTEREST

Ownership by the assignee is established as follows:

An assignment from the inventor(s) of the matter identified above, which was recorded in  
the PTO on January 26, 2004 at Reel 014923, Frame 0734.


### COPIES OF DOCUMENTS IN CHAIN OF TITLE

Copies of the assignment(s) or other document(s) in the chain of title are attached as follows:

Date: \_\_\_\_\_

\_\_\_\_\_  
Name:

Title:



Docket No. 700953-54440

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Dennis L. Panicali et al.

Application No.:	10/660,369	Group No.:	1614
Filed:	09/11/2003	Examiner:	To be assigned
Confirmation No.:	5464	Customer No.:	50187
For:	TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN VIVO		

**MAIL STOP PETITION**

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)**

I hereby certify that the attached correspondence comprising:

1. Certificate of Mailing (2 pp.);
2. Transmittal Form (2 pp.);
3. Fee Transmittal in duplicate (2 pp.);
4. Amendment, Request and Fee to Delete and/or Add to Original Erroneously Named or Not Named Inventor(s) in Nonprovisional Application – Declaration (37 C.F.R. § 1.48(a)) in duplicate (4 pp.);
5. Statement of Non-Deceptive Intent to Accompany Request for Correction of Inventorship Under 37 C.F.R. § 1.48(a) – J. Schlom (1 pg.);
6. Supplemental Declaration and Power of Attorney – executed by all inventors 3 originals (12 pp.);
7. Assent of Assignee to Correction and/or Addition of Inventor(s) – Therion Biologics Corporation (2 pp.);
8. Statement Under 37 C.F.R. § 3.73(b) Establishing Right of Assignee to Take Action – Therion Biologics Corporation (2 pp.);
9. Assent of Assignee to Correction and/or Addition of Inventor(s) – The Board of Trustees of the Leland Stanford Junior University (2 pp.);
10. Statement Under 37 C.F.R. § 3.73(b) Establishing Right of Assignee to Take Action – The Board of Trustees of the Leland Stanford Junior University (2 pp.); and
11. Return Receipt Postcard.



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Dennis L. Panicali et al.

Application No.: 10/660,369

Group No.: 1614

Filed: 09/11/2003

Examiner: To be assigned

Confirmation No.: 5464

Customer No.: 50187


For: TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL  
COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE  
IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS  
IN VIVO


is being deposited with the United States Postal Service, with sufficient postage, as first class  
mail in an envelope addressed to:

**MAIL STOP PETITION**  
**Commissioner for Patents**  
**P. O. Box 1450**  
**Alexandria, VA 22313-1450**

on December 7, 2005.

Linda M. Ginsberg

  
\_\_\_\_\_  
**Signature of person mailing paper**



PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/660,369
Filing Date	September 11, 2003
First Named Inventor	Dennis L. Panicali
Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	700953-54440

**ENCLOSURES (Check all that apply)**

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input checked="" type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): See the attached additional enclosures
---	---	--

**Remarks**

The Commissioner is hereby authorized to charge any fee deficiency or credit any overpayment to the Nixon Peabody LLP Deposit Account No. 50-0850.

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Nixon Peabody LLP		
Signature			
Printed name	Ronald I. Eisenstein		
Date	12/7/05	Reg. No.	30,628

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Linda M. Ginsberg	Date	12/07/2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



**TRANSMITTAL FORM  
(PTO/SB/21)**

**ADDITIONAL ENCLOSURES**

Application Number	10/660,369
Filing Date	September 11, 2003
First Named Inventor	Dennis L. Panicali
Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	700953-54440

**Certificate of Mailing**

Amednment, Request and Fee to Delete and/or Add Inventor

Statement of Non-Deceptive Intent to Accompany Request for Correction of Inventorship

**Supplemental Declaration and Power of Attorney**

Assent of Assignee to Correction and/or Addition of Inventor - Therion Biologics Corportion

**Statement under 37 C.F.R. 3.73(b) - Therion Biologics Corporation**

Assent of Assignee to Correction and/or Addition of Inventor - The Board of Trustees of the Leland Stanford Junior University

Statement under 37 C.F.R. 3.73(b) - The Board of Trustees of the Leland Stanford Junior University

**Return Receipt Postcard**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.  
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

# FEE TRANSMITTAL

## For FY 2005

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 130.00

### Complete if Known

Application Number	10/660,369
Filing Date	September 11, 2003
First Named Inventor	Dennis L. Panicali
Examiner Name	To be assigned
Art Unit	1614
Attorney Docket No.	700953-54440

### METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): \_\_\_\_\_  
☒ Deposit Account Deposit Account Number: 50-0850 Deposit Account Name: Nixon Peabody LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee  
☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

### FEE CALCULATION

#### 1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

#### 2. EXCESS CLAIM FEES

##### Fee Description

Each claim over 20 (including Reissues)  
Each independent claim over 3 (including Reissues)  
Multiple dependent claims

Fee (\$)	Small Entity Fee (\$)
	Fee (\$)
50	25
200	100
360	180
Multiple Dependent Claims	
Fee (\$)	Fee Paid (\$)

Total Claims Extra Claims Fee (\$)

- 20 or HP = x =

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims Extra Claims Fee (\$)

- 3 or HP = x =

HP = highest number of independent claims paid for, if greater than 3.

#### 3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$)

- 100 = / 50 = (round up to a whole number) x 250.00 = 0.00

#### 4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Petition Fee

Fees Paid (\$)

130.00

#### SUBMITTED BY

Signature	<i>Ronald I. Eisenstein</i>	Registration No. (Attorney/Agent)	30,628	Telephone	617-345-6054
Name (Print/Type)	Ronald I. Eisenstein	Date	December 7, 2005		

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.